Table V.
Summary table to show sub-clinical infection (as measured by FMDV isolation from oropharyngeal fluids and/or nasal and saliva secretions) and persistence in sheep following vaccination with FMD vaccines formulated for emergency use.
| Vaccine | Challenge | Days vaccinated before exposure |
Virus isolation (or viral RNA recovery) from oropharyngeal fluids (weeks post challenge) |
NSABa | Ref. | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |||||||||
| O1 BFS 1860a 19.8μg/dosec Aqueousd |
Homologous indirect aerosol from 4 infectious pigs for 2 h |
7 | 4/4b | 3/4 | 1/4 | [36] | ||||||||
| O1 BFS 1860 9.9μg/dose Aqueous |
7 | 4/4 | 2/4 | 2/4 | ||||||||||
| 0 | 4/4 | 1/4 | 0/4 | |||||||||||
| O1 Lausanne 3.05 μg/dose Oil |
Homologous indirect aerosol from 3 infectious pigs for 2 h |
10 | 0/3 | 0/3 | [19] | |||||||||
| 6 | 1/3 | 0/3 | ||||||||||||
| 4 | 3/3 | 1/3 | ||||||||||||
| 3 | 0/3 | 0/3 | ||||||||||||
| O1 Lausanne 3.05 μg/dose Aqueous |
10 | 0/3 | 0/3 | |||||||||||
| 6 | 1/3 | 1/3 | ||||||||||||
| 4 | 0/3 | 0/3 | ||||||||||||
| 3 | 1/3 | 1/3 | ||||||||||||
| 0 | 4/4 | 4/4 | ||||||||||||
| Asia 1 India 8/79 | Homologous indirect aerosol from 3 infectious pigs for 4 h |
10 | 2/3 | 1/3 | ||||||||||
| 6 | 0/3 | 1/3 | ||||||||||||
| 2.25 μg/dose Oil |
4 | 0/3 | 0/3 | |||||||||||
| 3 | 0/3 | 0/3 | ||||||||||||
| 0 | 0/2 | 1/3 | ||||||||||||
| C1 Oberbayern 1.4 μg/dose Oil |
Homologous indirect aerosol from 3 infectious pigs for 4 h |
11 | 0/3 | 0/3 | 0/3 | 0/3 | See footnote 2 |
|||||||
| 7 | 0/3 | 0/3 | 0/3 | 0/3 | ||||||||||
| 5 | 3/3 | 0/3 | 0/3 | 1/3 | ||||||||||
| 4 | 0/3 | 0/3 | 1/3 | 0/3 | ||||||||||
| 11 | 0/3 | 0/3 | 0/3 | 0/3 | ||||||||||
| C1 Oberbayern 1.4 μg/dose Aqueous |
7 | 0/3 | 0/3 | 0/3 | 0/3 | |||||||||
| 5 | 1/3 | 1/3 | 1/3 | 1/3 | ||||||||||
| 4 | 0/3 | 0/3 | 0/3 | 0/3 | ||||||||||
| 0 | 4/6 | 3/6 | 4/6 | 3/6 | ||||||||||
| O1 Lausanne 3.05 μg/dose Aqueous |
Homologous indirect aerosol from 2 infectious pigs for 4 h |
14 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7d | [10] | ||||
| (0/7)c | (0/7) | (0/7) | (0/7) | (0/7) | (0/7) | (0/7) | ||||||||
| O1 Lausanne 0.30 μg/dose Aqueous |
14 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | ||||||
| (0/7) | (0/7) | (0/7) | (0/7) | (0/7) | (0/7) | |||||||||
| O1 Lausanne 0.076 μg/dose Aqueous |
14 | 3/7 | 1/7 | 3/7 | 2/7 | 1/7 | 2/7 | 2/7 | ||||||
| (3/7) | (1/7) | (2/7) | (0/7) | (0/7) | (0/7) | |||||||||
| 0 | 5/7 | 6/7 | 7/7 | 4/7 | 3/7 | 1/7 | 7/7 | |||||||
| (5/7) | (2/7) | (6/7) | (6/7) | (3/7) | (5/7) | |||||||||
| O1 Manisa ? (18 PD50 for cattle) Oil |
Semi- heterologous indirect aerosol from 3 infectious pigs for 9 h |
10 | 1/10 | 1/10 | 0/10 | 0/10 | 1/10 | [52] | ||||||
| (2/10) | (2/10) | (1/10) | (3/10) | (1/10) | 2/10 | |||||||||
| 4 | 1/10 | 1/10 | 2/10 | 1/10 | 1/10 | |||||||||
| (2/10) | (2/10) | (3/10) | (3/10) | (2/10) | 6/10 | |||||||||
| 0 | 4/8 | 0/8 | 2/8 | 1/8 | 2/8 | |||||||||
| (8/8) | (6/8) | (7/8) | (4/8) | (3/8) | 8/8 | |||||||||
a
Non structural antibody
b
number of animals from which FMDV recovered/total number of animals
c
number of animals which seroconverted to non-structural proteins/total number of animals
d
number of animals from which viral RNA recovered/total number of animals.